Chris Frost

List of Publications by Year
in descending order

71 papers	3,299 citations	218381 26 h-index	149479 56 g-index
89 all docs	89 docs citations	89 times ranked	5149 citing authors

#	Article	IF	Citations
1	Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. BMJ: British Medical Journal, 1997, 314, 112-112.	2.4	538
2	Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet, The, 2014, 383, 2213-2221.	6.3	361
3	One Year Treatment with Salmeterol Compared with Beclomethasone in Children with Asthma. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 688-695.	2.5	301
4	Correcting for regression dilution bias: comparison of methods for a single predictor variable. Journal of the Royal Statistical Society Series A: Statistics in Society, 2000, 163, 173-189.	0.6	242
5	Addition of Salmeterol versus Doubling the Dose of Beclomethasone in Children with Asthma. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 213-219.	2.5	209
6	Variability and determinants of total homocysteine concentrations in plasma in an elderly population. Clinical Chemistry, 1998, 44, 102-107.	1.5	128
7	Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurology, The, 2017, 16, 591-600.	4.9	95
8	Alzheimer's disease first symptoms are age dependent: Evidence fromÂthe NACC dataset. Alzheimer's and Dementia, 2015, 11, 1349-1357.	0.4	93
9	Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. The Cochrane Library, 2017, 2017, CD010369.	1.5	88
10	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimerâ€™s disease: a longitudinal cohort study. Molecular Psychiatry, 2021, 26, 5967-5976.	4.1	76
11	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 19.	3.0	65
12	The prevalence of depression in general hospital inpatients: a systematic review and meta-analysis of interview-based studies. Psychological Medicine, 2018, 48, 2285-2298.	2.7	64
13	Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. NeuroImage, 2015, 123, 149-164.	2.1	63
14	A Comparison of the Kampala Trauma Score (KTS) with the Revised Trauma Score (RTS), Injury Severity Score (ISS) and the TRISS Method in a Ugandan Trauma Registry. European Journal of Trauma and Emergency Surgery, 2003, 29, 392-398.	0.3	50
15	Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntingtonâ€™s Disease. Journal of the International Neuropsychological Society, 2016, 22, 595-608.	1.2	44
16	APOE Îµ4 status is associated with white matter hyperintensities volume accumulation rate independent of AD diagnosis. Neurobiology of Aging, 2017, 53, 67-75.	1.5	44
17	The analysis of repeated â€˜directâ€™ measures of change illustrated with an application in longitudinal imaging. Statistics in Medicine, 2004, 23, 3275-3286.	0.8	43
18	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: AÂserial magnetic resonance imaging study. Alzheimer's and Dementia, 2018, 14, 43-53.	0.4	42

#	ARTICLE	IF	CITATIONS
19	A Metabolic Study of Huntington's Disease. PLoS ONE, 2016, 11, e0146480.	1.1	41
20	Does depression treatment improve the survival of depressed patients with cancer? A long-term follow-up of participants in the SMaRT Oncology-2 and 3 trials. Lancet Psychiatry,the, 2018, 5, 321-326.	3.7	40
21	Silent brain infarcts on diffusion-weighted imaging after carotid revascularisation: A surrogate outcome measure for procedural stroke? A systematic review and meta-analysis. European Stroke Journal, 2019, 4, 127-143.	2.7	35
22	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. Neurobiology of Aging, 2016, 39, 99-107.	1.5	34
23	Major Depression and Survival in People With Cancer. Psychosomatic Medicine, 2021, 83, 410-416.	1.3	33
24	CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease. Neurobiology of Aging, 2020, 91, 5-14.	1.5	30
25	Corpus Callosal Atrophy in Premanifest and Early Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 517-526.	0.9	29
26	Combining optical coherence tomography with visual field data to rapidly detect disease progression in glaucoma: a diagnostic accuracy study. Health Technology Assessment, 2018, 22, 1-106.	1.3	29
27	Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run-in period increase efficiency?. Statistics in Medicine, 2008, 27, 3717-3731.	0.8	28
28	Correcting for measurement error in binary and continuous variables using replicates. Statistics in Medicine, 2001, 20, 3441-3457.	0.8	26
29	Findings of Impaired Hearing in Patients With Nonfluent/Agrammatic Variant Primary Progressive Aphasia. JAMA Neurology, 2019, 76, 607.	4.5	26
30	The Support to Rural India's Public Education System (STRIPES) Trial: A Cluster Randomised Controlled Trial of Supplementary Teaching, Learning Material and Material Support. PLoS ONE, 2013, 8, e65775.	1.1	25
31	A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington's Disease. PLoS ONE, 2015, 10, e0138848.	1.1	22
32	Short-interval observational data to inform clinical trial design in Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1291-1298.	0.9	22
33	Effects of community health interventions on under-5 mortality in rural Guinea-Bissau (EPICS): a cluster-randomised controlled trial. The Lancet Global Health, 2016, 4, e328-e335.	2.9	22
34	The effect of measurement error in risk factors that change over time in cohort studies: do simple methods overcorrect for 'regression dilution'?. International Journal of Epidemiology, 2005, 34, 1359-1368.	0.9	20
35	Inconsistent emotion recognition deficits across stimulus modalities in Huntington×³s disease. Neuropsychologia, 2014, 64, 99-104.	0.7	20
36	Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, 631-642.	1.2	20

#	Article	IF	Citations
37	Acupuncture for Irritable Bowel Syndrome: 2-Year Follow-Up of a Randomised Controlled Trial. Acupuncture in Medicine, 2017, 35, 17-23.	0.4	19
38	Different independent associations of depression and anxiety with survival in patients with cancer. Journal of Psychosomatic Research, 2020, 138, 110218.	1.2	19
39	The age-dependent associations of white matter hyperintensities and neurofilament light in early- and late-stage Alzheimer's disease. Neurobiology of Aging, 2021, 97, 10-17.	1.5	18
40	Use of hierarchical models for meta-analysis: experience in the metabolic ward studies of diet and blood cholesterol. , 1999, 18, 1657-1676.		17
41	Plasma amyloid-Î² ratios in autosomal dominant Alzheimerâ€™s disease: the influence of genotype. Brain, 2021, 144, 2964-2970.	3.7	16
42	Navigational cue effects in Alzheimer's disease and posterior cortical atrophy. Annals of Clinical and Translational Neurology, 2018, 5, 697-709.	1.7	15
43	Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	14
44	The HOME Study: study protocol for a randomised controlled trial comparing the addition of Proactive Psychological Medicine to usual care, with usual care alone, on the time spent in hospital by older acute hospital inpatients. Trials, 2019, 20, 483.	0.7	13
45	Design optimization for clinical trials in earlyâ€stage manifest Huntington's disease. Movement Disorders, 2017, 32, 1610-1619.	2.2	11
46	Detection and localisation of hesitant steps in people with Alzheimer's disease navigating routes of varying complexity. Healthcare Technology Letters, 2019, 6, 42-47.	1.9	11
47	Test-Retest Reliability of Diffusion Tensor Imaging in Huntingtonâ€™s Disease. PLOS Currents, 2014, 6, .	1.4	11
48	How much can we remedy very low learning levels in rural parts of low-income countries? Impact and generalizability of a multi-pronged para-teacher intervention from a cluster-randomized trial in the Gambia. Journal of Development Economics, 2021, 148, 102539.	2.1	10
49	The Potential of Composite Cognitive Scores for Tracking Progression in Huntington's Disease. Journal of Huntington's Disease, 2014, 3, 197-207.	0.9	8
50	The association between anthropometric measures of adiposity and the progression of carotid atherosclerosis. BMC Cardiovascular Disorders, 2020, 20, 138.	0.7	8
51	Is improvement in comorbid major depression associated with longer survival in people with cancer? A long-term follow-up of participants in the SMaRT Oncology-2 and 3 trials. Journal of Psychosomatic Research, 2019, 116, 106-112.	1.2	7
52	Reflection on modern methods: calculating a sample size for a repeatability sub-study to correct for measurement error in a single continuous exposure. International Journal of Epidemiology, 2019, 48, 1721-1726.	0.9	6
53	Suicidal Thoughts in Patients With Cancer and Comorbid Major Depression: Findings From a Depression Screening Program. Journal of the Academy of Consultation-Liaison Psychiatry, 2022, 63, 251-259.	0.2	6
54	Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance. PLOS Currents, 2016, 8, .	1.4	6

#	ARTICLE	IF	CITATIONS
55	Depression and anxiety during the year before death from cancer. Journal of Psychosomatic Research, 2022, 158, 110922.	1.2	5
56	The prevalence of anxiety in general hospital inpatients: A systematic review and meta-analysis. General Hospital Psychiatry, 2021, 72, 131-140.	1.2	4
57	Effect of adiposity on differences in carotid plaque burden in studies conducted in Norway and Russia: a cross-sectional analysis of two populations at very different risk of cardiovascular mortality. BMJ Open, 2020, 10, e036583.	0.8	3
58	The HOME Study: Statistical and economic analysis plan for a randomised controlled trial comparing theÂaddition of Proactive Psychological Medicine to usual care, with usual care alone, on the Âtime spent in hospital by older acute hospital inpatients. Trials, 2020, 21, 373.	0.7	3
59	Laughter as a paradigm of socio-emotional signal processing in dementia. Cortex, 2021, 142, 186-203.	1.1	3
60	Remedial after-school support classes offered in rural Gambia (The SCORE trial): study protocol for a cluster randomized controlled trial. Trials, 2015, 16, 574.	0.7	2
61	Linked symptom monitoring and depression treatment programmes for specialist cancer services: protocol for a mixed-methods implementation study. BMJ Open, 2017, 7, e016186.	0.8	2
62	Effects of lighting variability on locomotion in posterior cortical atrophy. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12077.	1.8	2
63	Power and sample-size calculations for trials that compare slopes over time: Introducing the slopepower command. The Stata Journal, 2021, 21, 575-601.	0.9	2
64	A safety evaluation of an extrafine aerosol of beclomethasone dipropionate in 6161 patients using the UK SAMM guidelines. Pharmaceutical Medicine, 2002, 16, 173-178.	0.4	1
65	Protocol for a cluster randomised trial in Madhya Pradesh, India: community health promotion and medical provision and impact on neonates (CHAMPION2); and support to rural Indiaâ€™s public education system and impact on numeracy and literacy scores (STRIPES2). Trials, 2020, 21, 569.	0.7	1
66	A limitation of genetic epidemiological analysis when associations are genuinely J-shaped illustrated using a prospective study of alcohol consumption and vascular disease. International Journal of Epidemiology, 2022, 50, 1757-1760.	0.9	1
67	Safety Assessment of Marketed Medicines (SAMM) studies: problems addressed but problems raised?. Pharmaceutical Medicine, 2002, 16, 167-169.	0.4	0
68	P3-062 Predictors and correlates of inter-individual variation in MRI derived atrophy rates in Alzheimer's disease. Neurobiology of Aging, 2004, 25, S369.	1.5	0
69	O5-06-03: IMPACT OF BASELINE ADJUSTMENT FOR VASCULAR RISK FACTORS ON SAMPLE SIZE FOR ATROPHY OUTCOMES IN ALZHEIMER'S DISEASE CLINICAL TRIALS. , 2014, 10, P302-P303.		0
70	White matter hyperintensity increases are a feature of familial AD and are associated with increased brain atrophy. Alzheimer's and Dementia, 2020, 16, e038925.	0.4	0
71	â€˜Do not attempt cardiopulmonary resuscitationâ€™ (DNACPR)â€"difficulty in discussions with older medical inpatients and their families: a survey of hospital doctors. BMJ Supportive and Palliative Care, 2021, , bmjspcare-2021-003151.	0.8	0